Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The following patents are patents granted by Daewoong Pharmaceutical and Avacta - Patent 1: “Method for producing mesoderm stem cells from human pluripotent stem cells and mesoderm stem cells produced thereby” patents registered in 8 countries - Patent 2: Registered patents for “Modified stefin A scaffold proteins” in 4 countries
https://www-koreabio-org.translate.goog/m48_view.php?idx=11&_x_tr_sl=ko&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
Sorry finger trouble meant "Great find "
Freat find gadgie dated 2nd July 2022
Liked this section : Wonder if they complered Series B funding ?
"CEO Yoo said, “Currently, AFX001, the first pipeline of Apicel Therapeutics, is about to transfer its technology to a GMP facility beyond the laboratory-level development stage. We plan to build a cell bank within this year and use it to produce drugs for clinical trials.”
CEO Yoo said, “We recently attracted investments in Series A and Bridge. We have secured research expenses for the next two to three years,” he said. At the same time, we will start the AFX001 clinical trial for organ transplant rejection and graft-versus-host disease to prove differentiated efficacy.”
Lastly, CEO Yoo expressed confidence that “Apicell Therapeutics wants to develop a stem cell-based CAR-T treatment.”
CEO Yoo, who is leading Apicell Therapeutics, has accumulated R&D experience in biopharmaceutical and genome fields through Samsung Advanced Institute of Technology, Samsung Bioepis, and Theragen Bio. Afterwards, he served as the head of the cell therapy center and the head of the C&D center of Daewoong Pharmaceutical. .
When asked why he joined Apicell Therapeutics, CEO Yoo said, “When I served as the head of Daewoong Pharmaceutical’s cell therapy center, I fell in love with the potential and potential of the DW-MSC platform. For this reason, as the head of the C&D center, I was focused on finding a partner who could strengthen the immune function through genetic manipulation of mesenchymal stem cells. He also accepted this will at the level.”
CEO Yoo said, “Currently, AFX001, the first pipeline of Apicel Therapeutics, is about to transfer its technology to a GMP facility beyond the laboratory-level development stage. We plan to build a cell bank within this year and use it to produce drugs for clinical trials.”
CEO Yoo said, “We recently attracted investments in Series A and Bridge. We have secured research expenses for the next two to three years,” he said. At the same time, we will start the AFX001 clinical trial for organ transplant rejection and graft-versus-host disease to prove differentiated efficacy.”
Lastly, CEO Yoo expressed confidence that “Apicell Therapeutics wants to develop a stem cell-based CAR-T treatment.”
?? : ????(http://www.docdocdoc.co.kr)
https://www-docdocdoc-co-kr.translate.goog/news/articleView.html?idxno=2024632&_x_tr_sch=http&_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en-US&_x_tr_pto=wapp
Interview] Jong-sang Yoo, CEO of Apicell
Therapeutics “Goal to develop CAR-T treatment for stem cell”
Recently, there is a company that draws attention from the industry by signing active partnerships with domestic bio companies. That's Apicell Therapeutics. GeneScript Probio, Biocytogen, and Korea Non-clinical Technology Support Center are showing off their presence by holding hands one after another.
In addition, it has a unique history of being a mesenchymal stem cell-based next-generation gene and cell therapy development company established through a joint investment between Daewoong Pharmaceutical, a domestic pharmaceutical company, and Avacta Life Science, a British company.
Accordingly, this paper met with Jongsang Yoo, CEO of Apicell Therapeutics in person to hear about Apicell Therapeutics' platform technology, future R&D plans, and mid- to long-term corporate vision.
First, when interest in gene and cell therapy is growing recently and many companies are jumping into R&D, when asked what Apicel Therapeutics' unique technology and strengths are, CEO Yoo Jong-sang said, "Securing excellent platform technology is difficult with other bio companies. It's different," he said.
CEO Yoo said, “The AFX platform technology developed by Apicell Therapeutics is based on Daewoong Pharmaceutical’s mesenchymal stem cell platform ‘DW-MSC’ technology. DW-MSC is a technology that overcomes the limitations of adult tissue-derived mesenchymal stem cells, which were difficult to subculture for a long time.”
He continued, “In addition, to further strengthen the immunomodulatory function, the analogue 'Affimer' developed by Avacta is applied through genetic manipulation. It is now possible to develop a stem cell treatment with enhanced immunomodulatory ability through genetic manipulation.”
If so, what was the reason for bringing the technologies of the two companies together?
Regarding this, CEO Yoo said, “Immune cell development and stem cell development started at the same time. In the case of immune cell development, innovation such as CAR-T treatment has been achieved, while stem cell development has been stagnant. “I came to the conclusion that innovation can only be achieved by applying genetic manipulation to stem cells, like CAR-T treatment, rather than just emphasizing culture technology,” he said.
He continued, "I was looking for another platform technology that could be fused through genetic manipulation, and the meeting with Avacta took place," he explained.
According to CEO Yoo, Daewoong Pharmaceutical, which has been discovering partners for stem cell treatment development, held its first meeting with Avacta at the 2018 Bio International (BIO USA) event. In January 2019, the following year, the two companies met again at the JP Morgan Bio Health Conference